Mankind Pharma Ltd. - Research Center
543904 MANKIND Group (B) BSE data
Add to watchlist
| Results | |
| Statement |
Balance sheet
|
| More |
Balance sheet
(Rs crore)
| Mar ' 23 | Mar ' 22 | Mar ' 21 | Mar ' 20 | Mar ' 19 | |
|---|---|---|---|---|---|
| Sources of funds | |||||
| Owner's fund | |||||
| Equity share capital | 40.06 | 40.06 | 40.06 | 40.06 | 40.06 |
| Share application money | - | - | - | - | - |
| Preference share capital | - | - | - | - | - |
| Reserves & surplus | 7,743.85 | 6,028.72 | 4,694.21 | 3,611.39 | 3,024.76 |
| Loan funds | |||||
| Secured loans | - | 687.89 | 95.00 | - | 190.00 |
| Unsecured loans | - | - | - | - | - |
| Total | 7,783.91 | 6,756.67 | 4,829.27 | 3,651.45 | 3,254.82 |
| Uses of funds | |||||
| Fixed assets | |||||
| Gross block | 3,551.71 | 3,185.08 | 1,193.84 | 1,097.52 | 880.27 |
| Less : revaluation reserve | - | - | - | - | - |
| Less : accumulated depreciation | 409.49 | 298.56 | 206.43 | 152.76 | 102.36 |
| Net block | 3,142.22 | 2,886.52 | 987.41 | 944.76 | 777.91 |
| Capital work-in-progress | 494.78 | 386.57 | 165.57 | 147.62 | 211.11 |
| Investments | 3,102.23 | 2,148.44 | 2,396.89 | 1,783.67 | 1,698.01 |
| Net current assets | |||||
| Current assets, loans & advances | 2,631.89 | 2,991.33 | 2,330.46 | 1,655.05 | 1,184.92 |
| Less : current liabilities & provisions | 1,587.21 | 1,656.18 | 1,051.06 | 879.65 | 617.14 |
| Total net current assets | 1,044.68 | 1,335.15 | 1,279.40 | 775.39 | 567.78 |
| Miscellaneous expenses not written | - | - | - | - | - |
| Total | 7,783.91 | 6,756.67 | 4,829.27 | 3,651.45 | 3,254.82 |
| Notes: | |||||
| Book value of unquoted investments | 2,040.76 | 1,760.67 | 2,396.89 | 1,783.67 | 1,698.01 |
| Market value of quoted investments | 1,061.47 | 387.77 | - | - | - |
| Contingent liabilities | 168.37 | 275.47 | - | - | - |
| Number of equity sharesoutstanding (Lacs) | 4005.88 | 4005.88 | 4005.88 | 4005.88 | 4005.88 |
© 2024 Rediff.com India Limited. All rights reserved. Disclaimer - Terms of Service - Privacy Policy - Feedback
DISCLAIMER: All financials are on standalone basis